Hyeon-Jong Kim, Hyunjin Bang, Hyun-Jung Shim, Jun Eul Hwang, Sang-Hee Cho, Ik-Joo Chung, Seung Ji Kang, Jong Gwang Kim, Seung-Hoon Beom, A-Yeung Jang, Joon Young Song, Woo Kyun Bae
Received November 12, 2024 Accepted February 11, 2025 Published online February 12, 2025
Purpose
Current guidelines recommend vaccination at least two weeks before chemotherapy initiation to optimize the immune response despite limited evidence. Our previous study indicated no differences in short-term immune response for the 13-valent pneumococcal conjugate vaccine (PCV13) according to the vaccination timing. This study aims to investigate the long-term efficacy of PCV13 and clinical factors associated with the respective antibody response.
Materials and Methods
Patients with gastric or colorectal cancer who received adjuvant chemotherapy were enrolled and divided into two groups: vaccinated two weeks before chemotherapy (arm A) and vaccinated concurrently with chemotherapy (arm B). Serum samples were collected before vaccination and in one month, three years, and five years. Immune responses were measured using ELISA and multiplex opsonophagocytosis assay.
Results
Including 63 patients, both groups showed an initial increase in the geometric mean titers (GMTs) of opsonophagocytic activity and the geometric mean concentrations (GMCs) of serotype-specific IgG levels after one month, followed by a decline at three and five years, particularly for serotypes 1, 14, 18C, and 19A. Despite the decline, global protection was maintained for five years, although global response decreased. The two arms did not show significant differences in immunogenicity nor in factors such as vaccination timing, age, cancer type, or chemotherapy regimen.
Conclusion
Vaccination timing is not a significant factor for the immunogenicity of PCV13 in cancer patients undergoing adjuvant chemotherapy. Global protection against pneumococcal infection was sustained for >5 years, and global response remained in over half of patients.
Keun-Wook Lee, Sae-Won Han, Tae Won Kim, Joong Bae Ahn, Ji Yeon Baek, Sang Hee Cho, Howard Lee, Jin Won Kim, Ji-Won Kim, Tae-You Kim, Yong Sang Hong, Seung-Hoon Beom, Yongjun Cha, Yoonjung Choi, Seonhui Kim, Yung-Jue Bang
Cancer Res Treat. 2024;56(2):590-601. Published online December 7, 2023
Purpose
GC1118 is a novel antibody targeting epidermal growth factor receptor (EGFR) with enhanced blocking activity against both low- and high-affinity EGFR ligands. A phase 1b/2a study was conducted to determine a recommended phase 2 dose (RP2D) of GC1118 in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) (phase 1b) and to assess the safety and efficacy of GC1118 plus FOLFIRI as a second-line therapy for recurrent/metastatic colorectal cancer (CRC) (phase 2a).
Materials and Methods
Phase 1b was designed as a standard 3+3 dose-escalation study with a starting dose of GC1118 (3 mg/kg/week) in combination with biweekly FOLFIRI (irinotecan 180 mg/m2; leucovorin 400 mg/m2; 5-fluorouracil 400 mg/m2 bolus and 2,400 mg/m2 infusion over 46 hours) in patients with solid tumors refractory to standard treatments. The subsequent phase 2a part was conducted with objective response rate (ORR) as a primary endpoint. Patients with KRAS/NRAS/BRAF wild-type, EGFR-positive, recurrent/metastatic CRC resistant to the first-line treatment were enrolled in the phase 2a study.
Results
RP2D of GC1118 was determined to be 3 mg/kg/wk in the phase 1b study (n=7). Common adverse drug reactions (ADRs) observed in the phase 2a study (n=24) were acneiform rash (95.8%), dry skin (66.7%), paronychia (58.3%), and stomatitis (50.0%). The most common ADR of ≥ grade 3 was neutropenia (33.3%). ORR was 42.5% (95% confidence interval [CI], 23.5 to 62.0), and median progression-free survival was 6.7 months (95% CI, 4.0-8.0).
Conclusion
GC1118 administered weekly at 3 mg/kg in combination with FOLFIRI appears as an effective and safe treatment option in recurrent/metastatic CRC.
Citations
Citations to this article as recorded by
Drug combinations of camptothecin derivatives promote the antitumor properties Zhen Liu, Yajie Yuan, Ning Wang, Peng Yu, Yuou Teng European Journal of Medicinal Chemistry.2024; 279: 116872. CrossRef
Yae Jee Baek, Youn-Jung Lee, So Ra Park, Kyoo Hyun Kim, Seung-Hoon Beom, Choong-kun Lee, Sang Joon Shin, Sun Young Rha, Sinyoung Kim, Kyoung Hwa Lee, Jung Ho Kim, Su Jin Jeong, Nam Su Ku, Jun Yong Choi, Joon-Sup Yeom, Minkyu Jung, Jin Young Ahn
Cancer Res Treat. 2023;55(3):746-757. Published online February 9, 2023
Purpose We aimed to assess the humoral response to and reactogenicity of coronavirus disease 2019 (COVID-19) vaccination according to the vaccine type and to analyze factors associated with immunogenicity in actively treated solid cancer patients (CPs).
Materials and Methods Prospective cohorts of CPs, undergoing anticancer treatment, and healthcare workers (HCWs) were established. The participants had no history of previous COVID-19 and received either mRNA-based or adenovirus vector–based (AdV) vaccines as the primary series. Blood samples were collected before the first vaccination and after 2 weeks for each dose vaccination. Spike-specific binding antibodies (bAbs) in all participants and neutralizing antibodies (nAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wild-type, Delta, and Omicron variants in CPs were analyzed and presented as the geometric mean titer.
Results Age-matched 20 HCWs and 118 CPs were included in the analysis. The bAb seroconversion rate and antibody concentrations after the first vaccination were significantly lower in CPs than in HCWs. After the third vaccination, antibody levels in CPs with a primary series of AdV were comparable to those in HCWs, but nAb titers against the Omicron variant did not quantitatively increase in CPs with AdV vaccine as the primary series. The incidence and severity of adverse reactions post-vaccination were similar between CPs and HCWs.
Conclusion CPs displayed delayed humoral immune response after SARS-CoV-2 vaccination. The booster dose elicited comparable bAb concentrations between CPs and HCWs, regardless of the primary vaccine type. Neutralization against the Omicron variant was not robustly elicited following the booster dose in some CPs, implying the need for additional interventions to protect them from COVID-19.
Citations
Citations to this article as recorded by
Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study Hong-Hong Liu, Yunbo Xie, Bao-Peng Yang, Huan-Yue Wen, Peng-Hui Yang, Jin-E Lu, Yan Liu, Xi Chen, Meng-Meng Qu, Yang Zhang, Wei-Guo Hong, Yong-Gang Li, Junliang Fu, Fu-Sheng Wang Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis Tiantian Hua, Ru Fan, Yang Fan, Feng Chen Human Vaccines & Immunotherapeutics.2024;[Epub] CrossRef
A Three-Dose mRNA COVID-19 Vaccine Regime Produces Both Suitable Immunogenicity and Satisfactory Efficacy in Patients with Solid Cancers Urska Janzic, Urska Bidovec-Stojkovic, Peter Korosec, Katja Mohorcic, Loredana Mrak, Marina Caks, Maja Ravnik, Erik Skof, Matija Rijavec Vaccines.2023; 11(6): 1017. CrossRef
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients Christopher W. Dukes, Marine Potez, Jeffrey Lancet, Barbara J. Kuter, Junmin Whiting, Qianxing Mo, Brett Leav, Haixing Wang, Julie S. Vanas, Christopher L. Cubitt, Kimberly Isaacs-Soriano, Kayoko Kennedy, Julie Rathwell, Julian Diaz Cobo, Wesley O’Nan, Br Vaccines.2023; 12(1): 13. CrossRef
Purpose
Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies.
Materials and Methods
We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing
assay.
Results
Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments.
Conclusion
The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.
Citations
Citations to this article as recorded by
Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri Tumori Journal.2024; 110(1): 60. CrossRef
Vaccination of Adults With Cancer: ASCO Guideline Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather N. Moore, Heloisa P. Soares, Randy A. Taplitz, Edom S. Woldet Journal of Clinical Oncology.2024; 42(14): 1699. CrossRef
Cancer bronchopulmonaire M. Lachâtre, A. Lemaitre, C. Charlier, J. Mazières Revue des Maladies Respiratoires Actualités.2024; 16: e39. CrossRef
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) P. Pedrazzoli, A. Lasagna, I. Cassaniti, A. Piralla, A. Squeri, R. Bruno, P. Sacchi, F. Baldanti, M. Di Maio, G.D. Beretta, S. Cinieri, N. Silvestris ESMO Open.2023; 8(3): 101215. CrossRef
Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making Kay Choong See Vaccines.2023; 11(5): 908. CrossRef
Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study Tabitha M. Sabu, Vanita Noronha, Abhijith R. Rao, Anita Kumar, Shreya Gattani, Anant Ramaswamy, Anupa Pillai, Ratan Dhekale, Renita Castelino, Sharath Kumar, Arshiya Sehgal, Pallavi Rana, Vikram Gota, Rajendra Badwe, Kumar Prabhash Cancer Research, Statistics, and Treatment.2023; 6(1): 52. CrossRef
Review of Vaccination Recommendations in Guidelines for Non-Communicable Diseases with Highest Global Disease Burden among Adults 75 Years Old and Above Abdul Rahman Ishak, Yu Chun Hsieh, Harshitha Srinivasan, Kay Choong See Vaccines.2023; 11(6): 1076. CrossRef
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Gugl eClinicalMedicine.2023; 61: 102044. CrossRef
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer Subhadeep Das, Diptikanta Acharya Immunological Investigations.2023; 52(8): 1065. CrossRef
Vaccination anti-infectieuse : pour qui ? Quand ? Comment ? M. Lachâtre, M. Murris-Espin, J. Mazières Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S209. CrossRef
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial Laurie Spehner, Emeline Orillard, Antoine Falcoz, Quentin Lepiller, Adeline Bouard, Hamadi Almotlak, Stefano Kim, Elsa Curtit, Guillaume Meynard, Marine Jary, Charlee Nardin, Kamal Asgarov, Syrine Abdeljaoued, Ugo Chartral, Virginie Mougey, Myriam Ben Khe BMJ Oncology.2023; 2(1): e000054. CrossRef
Novel Pneumococcal Protein-Polysaccharide Conjugate Vaccine Based on Biotin-Streptavidin Mengze Guo, Xiaonan Guo, Chenxing Zhang, Shidong Zhu, Yue Zhang, Tiejun Gu, Wei Kong, Yongge Wu, Nancy E. Freitag Infection and Immunity.2022;[Epub] CrossRef
COVID-19 vaccination in cancer patients: a narrative review Suranjith L Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne, Buddhika Somawardana Journal of International Medical Research.2022;[Epub] CrossRef
Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study Hannah M. Garcia Garrido, Mirjam J. Knol, Jarom Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis International Journal of Infectious Diseases.2021; 106: 237. CrossRef
Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19? Ajit Venniyoor Indian Journal of Medical and Paediatric Oncology.2021; 42(01): 021. CrossRef
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment M. Peeters, L. Verbruggen, L. Teuwen, G. Vanhoutte, S. Vande Kerckhove, B. Peeters, S. Raats, I. Van der Massen, S. De Keersmaecker, Y. Debie, M. Huizing, P. Pannus, K. Neven, K.K. Ariën, G.A. Martens, M. Van Den Bulcke, E. Roelant, I. Desombere, S. Angui ESMO Open.2021; 6(5): 100274. CrossRef
Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults Nobuhiro Asai, Hiroshige Mikamo Microorganisms.2021; 9(11): 2342. CrossRef
Vaccination practices, efficacy, and safety in adults with cancer Laboni Sarkar, Vasu Babu Goli, Nandini Menon, Vijay Maruti Patil, Vanita Noronha, Kumar Prabhash Cancer Research, Statistics, and Treatment.2021; 4(3): 505. CrossRef
Incidence of Invasive Pneumococcal Disease Among Adults With Hematological and Solid Organ Malignancies in the Netherlands: A Population Based Cohort Study Hannah M. Garcia Garrido, Mirjam J. Knol, J. Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis SSRN Electronic Journal .2020;[Epub] CrossRef
Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
Cancer Res Treat. 2019;51(2):819-831. Published online September 27, 2018
Purpose
Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection.
Materials and Methods
This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values.
Results
Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis.
Conclusion
This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.
Citations
Citations to this article as recorded by
Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer Hirofumi Tazawa, Takahisa Suzuki, Akihisa Saito, Akira Ishikawa, Toshiaki Komo, Haruki Sada, Norimitsu Shimada, Naoto Hadano, Takashi Onoe, Takeshi Sudo, Yosuke Shimizu, Kazuya Kuraoka, Hirotaka Tashiro Journal of Gastrointestinal Surgery.2022; 26(2): 305. CrossRef
Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Renan Ribeiro, Leonardo Cardili, Bruno Zilberstein, Ivan Cecconello, Ulysses Ribeiro, Evandro Sobroza de Mello, Tiago Biachi de Castria Virchows Archiv.2021; 478(6): 1039. CrossRef
Epstein–Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy Marina Alessandra Pereira, Daniel Amadeus Molon Batista, Marcus Fernando Kodama Pertille Ramos, Leonardo Cardili, Renan Ribeiro e Ribeiro, Andre Roncon Dias, Bruno Zilberstein, Ulysses Ribeiro Jr, Ivan Cecconello, Venâncio Avancini Ferreira Alves, Evandro Journal of Surgical Research.2021; 261: 130. CrossRef
Cytotoxic T‐lymphocyte‐associated protein 4 in gastric cancer: Prognosis and association with PD‐L1 expression Marina Alessandra Pereira, Tiago Biachi de Castria, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Leonardo Cardili, Rafael Dyer Rodrigues de Moraes, Bruno Zilberstein, Sergio Carlos Nahas, Ulysses Ribeiro, Evandro Sobroza de Mello Journal of Surgical Oncology.2021; 124(7): 1040. CrossRef
Remnant gastric cancer: a neglected group with high potential for immunotherapy Marcus Fernando Kodama Pertille Ramos, Marina Alessandra Pereira, Tiago Biachi de Castria, Renan Ribeiro e Ribeiro, Leonardo Cardili, Evandro Sobroza de Mello, Bruno Zilberstein, Ulysses Ribeiro-Júnior, Ivan Cecconello Journal of Cancer Research and Clinical Oncology.2020; 146(12): 3373. CrossRef
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz, Elisa Lozano Cancers.2020; 12(8): 2116. CrossRef
Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer Seo Ree Kim, Kabsoo Shin, Jae Myung Park, Han Hong Lee, Kyo Yong Song, Sung Hak Lee, Bohyun Kim, Sang-Yeob Kim, Junyoung Seo, Jeong-Oh Kim, Sang-Young Roh, In-Ho Kim Journal of Gastric Cancer.2020; 20(4): 408. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis van den Ende, ter Veer, Mali, van Berge Henegouwen, Hulshof, van Oijen, van Laarhoven Cancers.2019; 11(4): 530. CrossRef
Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib. We examined the incidence and clinical characteristics of drug-induced ILD in Korean non-small cell lung carcinoma patients treated with gefitinib. Materials and Methods A retrospective cohort study was performed in non-small cell lung cancer (NSCLC) patients who started gefitinib treatment at Seoul National University Hospital from January 2002 through December 2011. Patients who developed new abnormal radiologic findings with respiratory symptoms after gefitinib treatment were defined as having possible adverse pulmonary reactions. The patients’ medical records were reviewed independently by investigators to identify the causes of pulmonary toxicities. Results Among the 1,114 patients evaluated, 128 patients (11.5%) developed pulmonary adverse reactions after taking gefitinib. An infectious complication occurred in 98 patients (8.8%) and 15 patients (1.3%) developed ILD. Nine of the 15 patients (60.0%) with gefitinib-induced ILD experienced a fatal clinical course that met either the Common Terminology Criteria for Adverse Events grade 4 (n=3) or grade 5 (n=6). In the multivariate analysis, a lower serum albumin level (≤ 3.0 g/dL) at baseline was significantly associated with the development of gefitinib-induced ILD (odds ratio, 3.91; 95% confidence interval, 1.20 to 12.71). Conclusion The incidence of gefitinib-induced ILD in Korean NSCLC patients was similar to that reported worldwide, but lower than values reported for Japanese population. ILD was usually a lifethreatening adverse effect of gefitinib, and the development of ILD was significantly associated with a lower baseline serum albumin level.
Citations
Citations to this article as recorded by
Risk factors for interstitial lung disease in patients with non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: A systematic review and meta-analysis Yosuke Fukuda, Yoshitaka Uchida, Koichi Ando, Ryo Manabe, Akihiko Tanaka, Hironori Sagara Respiratory Investigation.2024; 62(3): 481. CrossRef
Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats Wael A. Alanazi, Hussain N. Alhamami, Ali A. Alshamrani, Faleh Alqahtani, Abdulrahman Alshammari, Khalid Alhazzani, Mohammed Alswayyed Saudi Journal of Biological Sciences.2023; 30(2): 103522. CrossRef
Characteristics and risk of interstitial lung disease in dermatomyositis and polymyositis: a retrospective cohort study in Japan Qingqing Hu, Kuan-Chih Huang, Choo Hua Goh, Yumi Tsuchiya, Yanfang Liu, Hong Qiu Scientific Reports.2023;[Epub] CrossRef
Sensorineural hearing loss induced by gefitinib: A CARE-compliant case report and literature reviews Bao-chen Zhu, Wen-hua Yang, Mao Huang, Jin-gui Wang, Yan Liang, Zhen-zhen Lei, Sha-sha Zhang, Ying Wang, Xiao-di Sun, Ying Gong, Chun-miao Xue, Guo-dong Hua Medicine.2023; 102(45): e36010. CrossRef
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism Alessio Basolo, Antonio Matrone, Rossella Elisei, Ferruccio Santini Seminars in Cancer Biology.2022; 79: 197. CrossRef
Pulmonary toxicities of molecular targeted antineoplastic agents: a single-center 10-year experience Min-Young Lee, Seug Yun Yoon, Kyoung Ha Kim, Namsu Lee, Ha Youn Kim, Jung Hwa Hwang, Jong-Ho Won The Korean Journal of Internal Medicine.2021; 36(3): 689. CrossRef
Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China Xie Xiaohong, Wang Liqiang, Li Na, Lin Xinqing, Qin Yinyin, Liu Ming, Ouyang Ming, Han Qian, Luo Qun, Li Shiyue, Li Chunyan, Wang Xiaoqian, Yang Shuanying, Huang Wei, Liu Mei, Wang Ping, Zhou Chengzhi Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Osimertinib for Japanese patients with T790M‐positive advanced non‐small‐cell lung cancer: A pooled subgroup analysis Tomonori Hirashima, Miyako Satouchi, Toyoaki Hida, Makoto Nishio, Terufumi Kato, Hiroshi Sakai, Fumio Imamura, Katsuyuki Kiura, Isamu Okamoto, Kazuo Kasahara, Hirohiko Uchida, Sarah L. Vowler, Tetsuya Mitsudomi Cancer Science.2019; 110(9): 2884. CrossRef
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective Shigeki Saito, Joseph A. Lasky, Koichi Hagiwara, Yasuhiro Kondoh Respiratory Investigation.2018; 56(5): 375. CrossRef
Personalized chemotherapy of lung cancer: What the radiologist should know G.R. Ferretti, E. Reymond, A. Delouche, L. Sakhri, A. Jankowski, D. Moro-Sibilot, S. Lantuejoul, A.C. Toffart Diagnostic and Interventional Imaging.2016; 97(3): 287. CrossRef
Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas Rashmi R. Shah Drug Safety.2016; 39(11): 1073. CrossRef
Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer Namhun Lee, Kangwook Lee, Yoon-sik Kim, Chang-Gue Son, Jung-Hyo Cho, Hwa-Seung Yoo, Jonghoon Lee, Juyoung Ryu Journal of Pharmacopuncture.2016; 19(3): 259. CrossRef
Imagerie du suivi post-thérapeutique des traitements personnalisés systémiques du cancer bronchique G. Ferretti, E. Reymond, J. Cohen, A. Jankowski, M. Giaj-Levra, A.C. Toffart, D. Moro-Sibilot Revue des Maladies Respiratoires Actualités.2016; 8(5): 325. CrossRef